Kumquat Biosciences vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Kumquat Biosciences is an oncology-focused drug discovery company developing novel cancer therapeutics through internal research programs and academic collaborations; early-stage biotech with undisclosed funding; based in San Francisco.
About
Kumquat Biosciences is a San Francisco-based biotechnology company focused on oncology drug discovery and development. The company applies internal scientific expertise and collaborations with leading academic research institutions to identify and advance novel cancer therapeutic candidates. Kumquat operates in the early-to-mid stage of drug development, working on programs aimed at targeting cancer biology through mechanisms that may be underexplored in the current pharmaceutical industry pipeline.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.